Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Core Insights - Axogen, Inc. announced positive topline results from its REPOSE clinical study, demonstrating that Axoguard Nerve Cap is statistically superior to standard-of-care neurectomy in reducing total pain for symptomatic neuroma patients over a 12-month follow-up period [1][2] - The study met its primary endpoint for non-inferiority in pain reduction as measured by the visual analog scale, with a p-value of less than 0.05 [1][3] Company Overview - Axogen is a leader in developing and marketing surgical solutions for peripheral nerve injuries, focusing on technologies that enhance nerve regeneration and repair [5] - The company offers a comprehensive portfolio of products for both scheduled and emergent trauma procedures, addressing various conditions caused by nerve defects or injuries [6][7][8] Product Details - Axoguard Nerve Cap is a proprietary surgical implant made from porcine submucosal extracellular matrix, designed to protect peripheral nerve ends and reduce the development of symptomatic neuromas [4][8] - The product is part of a broader range of offerings that includes Avance® nerve graft and Axoguard Nerve Connector®, aimed at improving outcomes for patients with peripheral nerve damage [8]